33,300 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Seven Fleet Capital Management LP

Key Points

• Seven Fleet Capital Management acquired 33,300 shares of Xenon Pharmaceuticals during the second quarter, valued at approximately $2.08 million. Institutional investors collectively own 95.45% of the company.
• Xenon insiders sold 12,512 shares worth approximately $774,088 over the past three months, including substantial reductions by directors Steven Gannon and Gary Patou.
• Analysts maintain a generally positive outlook, with the stock carrying a consensus “Buy” rating and an average price target of $77.13, compared with a recent price of $63.79. The company also exceeded quarterly EPS expectations, reporting a loss of $1.11 per share versus the projected $1.16 loss.

Seven Fleet Capital Management LP purchased a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 33,300 shares of the biopharmaceutical company's stock, valued at approximately $2,084,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Kestra Advisory Services LLC purchased a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $33,000. Danske Bank A S purchased a new position in shares of Xenon Pharmaceuticals in the third quarter valued at approximately $32,000. Global Retirement Partners LLC acquired a new position in shares of Xenon Pharmaceuticals in the second quarter valued at approximately $53,000. Quantbot Technologies LP purchased a new stake in Xenon Pharmaceuticals during the 2nd quarter worth approximately $57,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Xenon Pharmaceuticals during the 4th quarter worth approximately $43,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Insider Activity at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 1,322 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director directly owned 24,896 shares in the company, valued at $1,322,973.44. This represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven Gannon sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the transaction, the director directly owned 1,870 shares of the company's stock, valued at approximately $119,792.20. This trade represents a 84.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 12,512 shares of company stock valued at $774,088. Insiders own 2.91% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on XENE. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Wall Street Zen raised Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 1st. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. HC Wainwright reiterated a "buy" rating and set a $74.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, August 10th. Finally, Needham & Company LLC lowered their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $77.13.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $63.79 on Thursday. The firm's fifty day moving average is $62.86 and its two-hundred day moving average is $56.22. The firm has a market cap of $6.17 billion, a PE ratio of -13.46 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a one year low of $35.60 and a one year high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.05. During the same quarter last year, the business earned ($1.07) EPS. Research analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source